JERUSALEM--(BUSINESS WIRE)--Yissum Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, today announced that scientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers. The novel drug is a small molecule named cis-ACCP, which is a prototype of a family of compounds that may be administered orally and was shown as highly effective in rodents without inducing any adverse side-effects. The development of the drug was a collaborative effort of the laboratories of Prof. Eli Breuer, Prof. Reuven Reich and Prof. Amnon Hoffman, all from the School of Pharmacy at the Hebrew University of Jerusalem. The work was published in the Journal of Medicinal Chemistry (Hoffman et al., electronic publication ahead of print: DOI: 10.1021/jm701087n).
